Publication highlights Puros Cancellous Particulate Allograft’s collagen microstructure and greater surface area for significantly higher mesenchymal stromal cellular (hBMSC) response compared to competitive freeze-dried allograft solutions Publication highlights Puros Cancellous Particulate Allograft’s collagen microstructure and greater surface area for significantly higher mesenchymal stromal cellular (hBMSC) response compared to competitive freeze-dried allograft solutions

Publication highlights Puros Cancellous Particulate Allograft’s collagen microstructure and greater surface area for significantly higher mesenchymal stromal cellular (hBMSC) response compared to competitive freeze-dried allograft solutions WESTMINSTER, Colo., March 23, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today

Shares of the MedTech company ZimVie (ZIMV) climbed ~15%, marking the highest intraday gain since November after announcing that two healthcare payers have issued positive medical…

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) with the stream of -0.09% also noticed, India ZimVie Inc. (NASDAQ:ZIMV) encountered a rapid change of -7.99% in the last hour of Tuesday’s trading session. On … The post Early Moves to Watch: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD -0.09%), ZimVie Inc. (NASDAQ:ZIMV -7.99%) appeared first on Stocks Equity .

ZimVie Inc. (NASDAQ:ZIMV) has seen 2.04 million shares traded in the last trading session. The company, currently valued at $151.27M, closed the last trade at $6.22 per share which meant it gained $0.42 on the day or 7.24% during that session. The ZIMV stock price is -365.27% off its 52-week high price of $28.94 and … ZimVie Inc. (ZIMV)’s Stock Price Falls Due To Weak Fundamental Momentum Read More »

As of Friday, ZimVie Inc.’s (NASDAQ:ZIMV) stock closed at $6.22, up from $5.80 the previous day. While ZimVie Inc. has overperformed by 7.24%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ZIMV fell by -74.41%, with highs and lows ranging from $28.94 to $5.05, whereas the […]

The specialty healthcare devices and tech purveyor disappointed with both fourth-quarter figures and full-year guidance.

In the current trading session, ZimVie Inc.’s (ZIMV) stock is trading at the price of $6.20, a fall of -40.73% over last night’s close. So, the stock is trading at a price that is -78.58% less than its 52-week high of $28.94 and -7.05% better than its 52-week low of $6.67. Based on the past […]

ZimVie (ZIMV) lost ~37% on Thursday to reach the lowest level since its IPO after reporting lower-than-expected Q4 2022 results and issuing underwhelming guidance. Read the full story here.

OncoSec Medical (ONCS) +44%. BioRestorative Therapies BRTX +32%. ZimVie (ZIMV) -45%. Cano Health (CANO) -23%.

ZIMV earnings call for the period ending December 31, 2022.

ZimVie Inc. (NASDAQ:NASDAQ:ZIMV) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ETCompany ParticipantsMarissa Bych - Investor RelationsVafa Jamali - President & Chief Executive…

ZimVie press release (ZIMV): Q4 Non-GAAP EPS of $0.16 misses by $0.05.Revenue of $229.12M (-12.4% Y/Y) misses by $7.88M.FY23 expected revenue of $825M - $850M, vs

WESTMINSTER, Colo., March 01, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today reported financial results for the fourth quarter and full year ended December 31, 2022. Management will host a corresponding conference call today, March 1, 2023, at 4:30 p.m. Eastern Time.

Two innovations enhancing ZimVie’s digital dentistry platform WESTMINSTER, Colo., Feb. 23, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced the launch of the RealGUIDE CAD and FULL SUITE modules, the latest innovations within ZimVie’s digital dentistry software platform. The CAD (computer-aided design) module

WESTMINSTER, Colo., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the fourth quarter and full year 2022 after market close on Wednesday, March 1, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZIMV has seen its SMA50 which is now 14.43%. In looking the SMA 200 we see that the stock has seen a -26.80%. XXII has seen its SMA50 which is … The post Mind-blowing stocks: ZimVie Inc. (NASDAQ:ZIMV -0.38%), 22nd Century Group, Inc. (NASDAQ:XXII 2.91%) appeared first on Stocks Equity .

Milestone aligns with ten-year anniversary of Mobi-C FDA approval for treatment of one and two levels of the cervical spine WESTMINSTER, Colo., Jan. 30, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that over 200,000 Mobi-C Cervical Discs have been implanted worldwide. This includes patients treated in over

Milestone aligns with ten-year anniversary of Mobi-C FDA approval for treatment of one and two levels of the cervical spine Milestone aligns with ten-year anniversary of Mobi-C FDA approval for treatment of one and two levels of the cervical spine